Terug
Ook genoteerd als
LZAGF
OTC
Dagbereik
€ 59,90
€ 60,71
52-Weeksbereik
€ 55,57
€ 73,85
Volume
16.841
50D / 200D Gem.
€ 67,17
/
€ 68,44
Vorige Slotkoers
€ 59,66
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 45,1 | 0,3 |
| P/B | 4,7 | 2,9 |
| ROE % | 10,3 | 3,7 |
| Net Margin % | 15,2 | 3,8 |
| Rev Growth 5Y % | 3,6 | 10,0 |
| D/E | 0,5 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 3,65
€ 3,49 – € 3,99
|
12 B | 1 |
| FY2029 |
€ 3,02
€ 2,89 – € 3,30
|
10 B | 1 |
| FY2028 |
€ 2,56
€ 2,45 – € 2,79
|
9,1 B | 1 |
Belangrijkste Punten
Revenue grew 3,63% annually over 5 years — modest growth
Earnings grew 49,21% over the past year
ROE of 10,28% — decent returns on equity
Net margin of 15,21% shows strong profitability
Debt/Equity of 0,46 — conservative balance sheet
Negative free cash flow of -194,83M
Groei
Revenue Growth (5Y)
3,63%
Revenue (1Y)-5,12%
Earnings (1Y)49,21%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
10,28%
ROIC7,38%
Net Margin15,21%
Op. Margin21,01%
Veiligheid
Debt / Equity
0,46
Current Ratio2,24
Interest Coverage8,09
Waardering
P/E Ratio
45,08
P/B Ratio4,68
EV/EBITDA35,30
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -5,12% | Revenue Growth (3Y) | -3,64% |
| Earnings Growth (1Y) | 49,21% | Earnings Growth (3Y) | 20,46% |
| Revenue Growth (5Y) | 3,63% | Earnings Growth (5Y) | -24,65% |
| Profitability | |||
| Revenue (TTM) | 6,24B | Net Income (TTM) | 949,00M |
| ROE | 10,28% | ROA | 5,00% |
| Gross Margin | 37,02% | Operating Margin | 21,01% |
| Net Margin | 15,21% | Free Cash Flow (TTM) | -194,83M |
| ROIC | 7,38% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,46 | Current Ratio | 2,24 |
| Interest Coverage | 8,09 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 45,08 | P/B Ratio | 4,68 |
| P/S Ratio | 6,86 | PEG Ratio | 0,74 |
| EV/EBITDA | 35,30 | Dividend Yield | 0,01% |
| Market Cap | 42,78B | Enterprise Value | 46,25B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6,24B | 6,57B | 6,72B | 6,22B | 5,41B |
| Net Income | 949,00M | 636,00M | 654,00M | 1,22B | 2,94B |
| EPS (Diluted) | 1,35 | 0,89 | 0,89 | 1,63 | 3,95 |
| Gross Profit | 2,31B | 2,16B | 1,95B | 2,44B | 2,11B |
| Operating Income | 1,31B | 964,00M | 880,00M | 1,54B | 851,00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 18,97B | 19,73B | 16,85B | 17,36B | 16,46B |
| Total Liabilities | 9,78B | 10,35B | 7,34B | 6,69B | 6,64B |
| Shareholders' Equity | 9,13B | 9,33B | 9,45B | 10,60B | 9,75B |
| Total Debt | 4,19B | 5,12B | 3,13B | 2,59B | 2,75B |
| Cash & Equivalents | 719,00M | 1,11B | 1,47B | 1,34B | 1,58B |
| Current Assets | 8,00B | 5,44B | 4,90B | 5,71B | 5,93B |
| Current Liabilities | 3,57B | 3,58B | 2,76B | 3,08B | 2,37B |